Today, a brief rundown of news involving Summit Therapeutics and Sellas Life Sciences, as well as updates from GSK, AstraZeneca, Eli Lilly and Biogen that you may have missed.
The Food and Drug Administration on Tuesday released a complete response letter detailing why it rejected Summit Therapeutics and Akeso’s ivonescimab for lung cancer. Summit said Sunday that the FDA’s decision was driven by the lack of clear survival benefit. The agency, though, also expressed concerns with the magnitude of the drug’s impact on tumor progression and how relevant the findings were to U.S. patients, according to the letter. Ivonescimab’s “modest” benefits don’t outweigh its additive safety risks, the regulator said, adding that Summit should run a new trial to win a clearance. A new application on its own is “unlikely to change the approval outcome,” wrote Leerink Partners analyst Daina Graybosch. — Ben Fidler
Shares in Sellas Life Sciences rocketed more than 160% Tuesday after the company posted data showing that its cancer vaccine “galinpepimut-S” extended the lives of acute myeloid leukemia patients in a Phase 3 trial. Sellas’ shot reduced the risk of death by 41% compared to standard therapy. Treatment recipients lived a median of 24 months versus 14.7 months for those on typical care. Dubbed “REGAL,” the trial studied the vaccine in leukemia patients who had already undergone at least two treatment lines and weren’t eligible for a stem cell transplant. Sellas said it would meet with the FDA in the near future to discuss a path forward, and could submit an approval application for as early as next year. — Gwendolyn Wu
The FDA has cleared another medicine GSK inherited in a June buyout of cancer drugmaker Nuvalent. The agency on Tuesday approved Nelkarmi, formerly known as neladalkib, for adults with previously treated, ALK-positive non-small cell lung cancer. That drug is the second newly approved medicine to come from GSK's $10.6 billion purchase of Nuvalent, following the July approval of another lung cancer treatment called Jideytro. Nelkarmi will initially compete with Pfizer's Lorbrena in the second-line setting. But the "larger opportunity" is in newly diagnosed patients, where a head-to-head trial against Roche's Alecensa is currently underway, wrote RBC Capital Markets analyst Trung Huynh. — Ben Fidler
The FDA on Monday also approved AstraZeneca’s gefurulimab for use in patients with generalized myasthenia gravis. Gefurulimab, which will be sold under the name “Klygefa,” is part of a class of drugs known as C5 inhibitors. AstraZeneca picked up the antibody in its acquisition of Alexion Pharmaceuticals, and it’s been billed as a more convenient, self-administered alternative to the infusible medicines — Soliris and Ultomiris — that Alexion brought to market for the autoimmune condition. — Gwendolyn Wu
Eli Lilly has struck a deal with biotechnology startup Stipple Bio in a cancer drug alliance that could be worth as much as $5.9 billion. The companies didn’t disclose Tuesday how much guaranteed cash is involved in the alliance, only noting that Lilly will make an upfront payment and an equity investment in Stipple. But the two will work together to find new targeted cancer medicines by harnessing a technology Stipple uses to identify molecules that precisely bind to “epitopes,” or regions exclusively found on tumor cells. — Gwendolyn Wu
Biogen is handing over $32 million up front to Trimtech Therapeutics in a bid to develop targeted protein degraders for neurodegenerative diseases. Trimtech’s drugs are small molecules capable of getting into the central nervous system and precisely degrading toxic protein buildups. Biogen has an option to exclusively license any therapies that emerge from the deal, and would cover development and commercialization costs afterward. Trimtech could receive up to $411 million in additional payouts, as well as royalties, if various milestones are met. — Gwendolyn Wu